Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

ShedRx vs Sumbare Wellness

Two GLP-1 desks, one scoreboard. We put ShedRx and Sumbare Wellness head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →
vs
No. 297 · Grade C

Sumbare Wellness

Visit Sumbare Wellness Full brief →

The verdict

ShedRx takes this head-to-head.

ShedRx scores 87 to 62 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.

That doesn't make Sumbare Wellness a bad call — it's best for shoppers who want one flat monthly price and a low-dose glp-1 option. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
86
78
Supply Reliability
86
57
Transparency
84
72
Access Breadth
85
50
Clinical Oversight
85
57
Track Record
86
45
ShedRxBrief Score 87 · 62Sumbare Wellness

Price, coverage & the tracker

ShedRxSumbare Wellness
Brief Score87/100 (B+)62/100 (C)
Semaglutide$199/moFrom $199/mo (all doses, compounded)
Tirzepatide$299/moFrom $199/mo (all doses, compounded)
CoverageNot disclosedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
On the trackerFallingprice fallingNewnew to the tracker, no prior reading

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

Sumbare Wellness: New to the tracker on 1 August 2026. The published line reads From $199/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.